Evidence map›Paper›PMID 31741780›Full record

ArticleOncoimmunology

A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.

Joshua D Bernstock, Nunzio Vicario, Li Rong, Pablo A Valdes, Bryan D Choi, Jason A Chen, Daniel DiToro, Diana S Osorio, Kara Kachurak, Florian Gessler and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Sprayed PAA-CaORegenerative biomaterials · 2023
    Article
  14. Review
  15. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Joshua D BernstockMedical Scientist Training Program, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-7814-3867
Nunzio VicarioDepartment of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, Catania, Italy.
Li RongDepartment of Pathology, Children's of Alabama, University of Alabama at Birmingham, Birmingham, AL, USA.
Pablo A ValdesDepartment of Neurosurgery, Brigham and Women's, Harvard Medical School, Boston, MA, USA.
Bryan D ChoiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jason A ChenMedical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Daniel DiToroMedical Scientist Training Program, University of Alabama at Birmingham, Birmingham, AL, USA.
Diana S OsorioDivision of Pediatric Hematology/Oncology, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.
Kara KachurakDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Florian GesslerDepartment for Neurosurgery, Goethe University Frankfurt, Frankfurt am Main, Germany.
James M JohnstonDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
T Prescott AtkinsonDivision of Pediatric Allergy, Asthma & Immunology, Department of Pediatrics and Diagnostic Mycoplasma Laboratory, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Richard J WhitleyDivision of Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Asim K BagDivision of Neuroradiology, Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
G Yancey GillespieDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
James M MarkertDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Dragan MaricFlow and Imaging Cytometry Core Facility, National Institute of Neurological Disordersand Stroke, National Institutes of Health (NINDS/NIH), Bethesda, MD, USA.
Gregory K FriedmanDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-6653-7420
University of Alabama at Birmingham · USBrigham and Women's Hospital · USChildren's of Alabama · USGoethe University Frankfurt · DEHarvard University · USNational Institutes of Health · USNationwide Children's Hospital · USUniversity of California, Los Angeles · USUniversity of Catania · IT

Funding

FDA HHS R01 FD005379
6 · The paper itself

Abstract

Immunotherapy with oncolytic herpes simplex virus-1 therapy offers an innovative, targeted, less-toxic approach for treating brain tumors. However, a major obstacle in maximizing oncolytic virotherapy is a lack of comprehensive understanding of the underlying mechanisms that unfold in CNS tumors/associated microenvironments after infusion of virus. We demonstrate that our multiplex biomarker screening platform comprehensively informs changes in both topographical location and functional states of resident/infiltrating immune cells that play a role in neuropathology after treatment with HSV G207 in a pediatric Phase 1 patient. Using this approach, we identified robust infiltration of CD8

Indexed as

checkpoint proteinsgliomaHSVmultiplex immunofluorescenceoncolytic virotherapy

Identifiers

PMID31741780
PMCPMC6844311
OpenAlexW2980587721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.